CD16A binding proteins useful for the reduction of a deleterious immune response are described. In one aspect, humanized anti-CD16A antibodies, optionally lacking effector function, are used for treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia.

 
Web www.patentalert.com

< Synthesis of conducto-magnetic polymers as nano-transducers in biosensor design

> Analysis of macromolecules, ligands and macromolecule-ligand complexes

~ 00423